Bispectral index monitoring: Optimizing anesthesia in rigid bronchoscopy.

Introduction: This study investigates the application of bispectral index (BIS) monitoring in rigid bronchoscopy to enhance anesthetic delivery and patient outcomes, a topic that remains underexplored. Materials and Methods: A retrospective analysis of 155 patients undergoing elective rigid bronchoscopy under general anesthesia was conducted. Patients were divided into BIS-monitored and conventional anesthesia groups. Inclusion criteria were adults aged over 18 years with American Society of Anesthesiologists (ASA) physical status I-IV. Result: No significant demographic differences were found between the groups. The BIS group showed significant reductions in propofol usage (231.40 ± 74.63 mg vs. 190.19 ± 91.83 mg, p= 0.003) and prednol dosage (94.27 ± 42.56 mg vs. 79.71 ± 18.97 mg, p= 0.020). Remifentanil administration approached statistical significance (56.99 ± 34.69 mcg vs. 45.36 ± 36.75 mcg, p= 0.055). Conclusions: No significant demographic differences were found between the groups. The BIS group showed significant reductions in propofol usage (231.40 ± 74.63 mg vs. 190.19 ± 91.83 mg, p= 0.003) and prednol dosage (94.27 ± 42.56 mg vs. 79.71 ± 18.97 mg, p= 0.020). Remifentanil administration approached statistical significance (56.99 ± 34.69 mcg vs. 45.36 ± 36.75 mcg, p= 0.055).

Comparison of Ventilator-Associated Pneumonia in Patients Admitted to Intensive Care for COVID-19 Versus Other Reasons: A Single-Centered Study.

OBJECTIVE: COVID-19 patients in intensive care usually need invasive mechanical ventilation due to advanced respiratory failure. Deep lym- phopenia, immunosuppressive agents, long-term mechanical ventilation, and sedation may lead to ventilator-associated pneumonia; an impor- tant cause of morbidity and mortality. This study evaluates the frequency, clinical features, causative pathogens, and outcomes of ventilator-asso ciated pneumonia in COVID-19 patients who require mechanical ventilation. METHODS: The files of patients hospitalized in our hospital's intensive care clinic between March 25, 2020, and January 15, 2021, in the first 2 peaks due to COVID-19 and other reasons were retrospectively reviewed. RESULTS: We found ventilator-associated pneumonia rate in COVID-19 patients as 52.2%, which was statistically significantly higher than in non-COVID patients (33.5%). Purulent sputum, leukocyte, and procalcitonin levels were found to be significantly higher in both groups develop- ing ventilator-associated pneumonia. However, fever levels were found to be significantly normal in both groups; 97.1% and 87%, respectively. High fever was observed in only 2.9% of COVID-19 patients who developed ventilator-associated pneumonia. We determined a mortality rate of 17 (100%) in the diabetes patients in the COVID-19 group, which was statistically significantly higher than in non-COVID-19 patients at 9 (64.3%). The mortality rate (86.1%) in those with COVID-19 was statistically significantly higher than in those without COVID-19 (64.9%). CONCLUSIONS: Ventilator-associated pneumonia is more common in COVID-19 patients treated with mechanical ventilation than in non- COVID patients. The predictive value of fever in the diagnosis is very low, and agent production together with increased purulent sputum will be more valuable in terms of diagnosis.